Overview
MediWound Q2 2025 revenue rises 43% sequentially, beating analysts' expectations
Net loss widens to $13.3 mln, driven by non-cash financial expenses
Co establishes strategic research collaborations with Essity and Convatec for EscharEx trials
Outlook
Company expects full operational capacity for NexoBrid by year-end 2025
Company received $3.6 mln from U.S. DoD for NexoBrid development
MediWound continues EscharEx Phase III trial enrollment with new partnerships
Result Drivers
NEXOBRID ADOPTION - U.S. adoption of NexoBrid continues to grow, with Vericel reporting 52% year-over-year revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $5.70 mln | $5.68 mln (6 Analysts) |
Q2 EPS | -$1.23 | ||
Q2 Net Income | -$13.30 mln | ||
Q2 Adjusted EBITDA | Miss | -$4.50 mln | -$4.25 mln (2 Analysts) |
Q2 Gross Profit | $1.30 mln | ||
Q2 Operating Income | -$5.70 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mediwound Ltd is $30.50, about 38.5% above its August 13 closing price of $18.75
Press Release: ID:nGNXb8gMFJ
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.